1,090 results

#203841-AAV2

Ready-to-use AAV2 particles produced from pAAV-hSyn-Kir2.1Mut-2A-mScarlet-KASH (#203841). In addition to the viral particles, you will also receive purified pAAV-hSyn-Kir2.1Mut-2A-mScarlet-KASH plasmid DNA. hSyn-driven expression of mutant murine Kir2.1 and mScarlet-KASH. These AAV preparations are suitable purity for injection into animals.

Ivo Spiegel

Roethler et al Neuron. 2023 Jun 20:S0896-6273(23)00399-

Feb. 9, 2026

Academic Institutions and Nonprofits only

#190155-AAV8

Ready-to-use AAV8 particles produced from AAV_pMBP-EGFP-caax (#190155). In addition to the viral particles, you will also receive purified AAV_pMBP-EGFP-caax plasmid DNA. MBP-driven EGFP expression in oligodendrocytes. These AAV preparations are suitable purity for injection into animals.

Brad Zuchero

Lam et al Nat Commun. 2022 Sep 23;13(1):5583. doi:

Feb. 6, 2026

Academic Institutions and Nonprofits only

#203840-AAV2

Ready-to-use AAV2 particles produced from pAAV-hSyn-Kir2.1WT-2A-mScarlet-KASH (#203840). In addition to the viral particles, you will also receive purified pAAV-hSyn-Kir2.1WT-2A-mScarlet-KASH plasmid DNA. hSyn-driven expression of Kir2.1 and mScarlet-KASH. These AAV preparations are suitable purity for injection into animals.

Ivo Spiegel

Roethler et al Neuron. 2023 Jun 20:S0896-6273(23)00399-

Feb. 6, 2026

Academic Institutions and Nonprofits only

#175274-AAV1

Ready-to-use AAV1 particles produced from pAAV-rtTA (#175274). In addition to the viral particles, you will also receive purified pAAV-rtTA plasmid DNA. Syn-driven expression of reverse tetracycline-controlled transactivator. These AAV preparations are suitable purity for injection into animals.

Wei Xu

Li et al Nat Methods. 2021 Nov 25. pii: 10.1038/s

Jan. 15, 2026

Academic Institutions and Nonprofits only

#230877-AAV2

Ready-to-use AAV2 particles produced from AiP15571: pAAV-AiE1426m-minBG-iCre(R297T)-BGHpA (Alias: CN5571) (#230877). In addition to the viral particles, you will also receive purified AiP15571: pAAV-AiE1426m-minBG-iCre(R297T)-BGHpA (Alias: CN5571) plasmid DNA. minBG-driven expression of iCre(R297T) in striatal Sst-Chodl interneurons. These AAV preparations are suitable purity for injection into animals.

Allen Institute for Brain Science, Jonathan Ting

Hunker et al Neuron. 2025 May 21;113(10):1507-1524.e1

Nov. 14, 2025

Academic Institutions and Nonprofits only

#224173-AAV2

Ready-to-use AAV2 particles produced from AiP13738 - pAAV-AiE0743m_3xC2-minBG-tdTomato-WPRE3-BGHpA (Alias: CN3738) (#224173). In addition to the viral particles, you will also receive purified AiP13738 - pAAV-AiE0743m_3xC2-minBG-tdTomato-WPRE3-BGHpA (Alias: CN3738) plasmid DNA. minBG-driven expression of tdTomato in striatal cholinergic neurons. These AAV preparations are suitable purity for injection into animals.

Allen Institute for Brain Science, Jonathan Ting

Hunker et al Neuron. 2025 May 21;113(10):1507-1524.e1

Nov. 14, 2025

Academic Institutions and Nonprofits only

#50458-AAVrg

Ready-to-use AAV Retrograde particles produced from pAAV-hSyn-DIO-rM3D(Gs)-mCherry (#50458). In addition to the viral particles, you will also receive purified pAAV-hSyn-DIO-rM3D(Gs)-mCherry plasmid DNA. hSyn-driven, Cre-dependent rM3D(Gs) receptor with an mCherry reporter for chemogenetic excitation. These AAV preparations are suitable purity for injection into animals.

Bryan Roth

Nov. 13, 2025

Academic Institutions and Nonprofits only

#213945-AAV1

Ready-to-use AAV1 particles produced from pAAV_BiSSTe4_ChR2_mCherry (#213945). In addition to the viral particles, you will also receive purified pAAV_BiSSTe4_ChR2_mCherry plasmid DNA. Expression of mCherry-tagged channelrhodopsin-2 under the control of the SST interneuron-targeting enhancer E4. These AAV preparations are suitable purity for injection into animals.

Gordon Fishell

Furlanis et al Neuron. 2025 May 21;113(10):1525-1547.e1

Sept. 23, 2025

Academic Institutions and Nonprofits only

#213939-AAV1

Ready-to-use AAV1 particles produced from pAAV_BiPVe4_GCaMP6f (#213939). In addition to the viral particles, you will also receive purified pAAV_BiPVe4_GCaMP6f plasmid DNA. Expression of GCaMP6f under the control of the chandelier cell-targeting enhancer E4. These AAV preparations are suitable purity for injection into animals.

Gordon Fishell

Furlanis et al Neuron. 2025 May 21;113(10):1525-1547.e1

Sept. 23, 2025

Academic Institutions and Nonprofits only

#213856-AAV1

Ready-to-use AAV1 particles produced from pAAV_BiVIPe4_ChR2_mCherry (#213856). In addition to the viral particles, you will also receive purified pAAV_BiVIPe4_ChR2_mCherry plasmid DNA. Expression of mCherry-tagged channelrhodopsin-2 under the control of the VIP interneuron-targeting enhancer E4. These AAV preparations are suitable purity for injection into animals.

Gordon Fishell

Furlanis et al Neuron. 2025 May 21;113(10):1525-1547.e1

Sept. 23, 2025

Academic Institutions and Nonprofits only

#61592-AAV8

Ready-to-use AAV8 particles produced from pX600-AAV-CMV::NLS-SaCas9-NLS-3xHA-bGHpA (#61592). In addition to the viral particles, you will also receive purified pX600-AAV-CMV::NLS-SaCas9-NLS-3xHA-bGHpA plasmid DNA. CMV-driven expression of SaCas9. These AAV preparations are suitable purity for injection into animals.

Feng Zhang

Ran et al Nature. 2015 Apr 1. doi: 10.1038/nature1

Sept. 22, 2025

Academic Institutions and Nonprofits only

#117382-AAV1

Ready-to-use AAV1 particles produced from pAAV-hSyn1-eYFP (#117382). In addition to the viral particles, you will also receive purified pAAV-hSyn1-eYFP plasmid DNA. hSyn-driven eYFP expression. These AAV preparations are suitable purity for injection into animals.

Viviana Gradinaru

Challis et al Nat Protoc. 2019 Feb;14(2):379-414. doi:

Aug. 15, 2025

Academic Institutions and Nonprofits only

#205997-AAV9

Ready-to-use AAV9 particles produced from pAAV_hSyn_WiChR_TS_mScarlet_ER (#205997). In addition to the viral particles, you will also receive purified pAAV_hSyn_WiChR_TS_mScarlet_ER plasmid DNA. hSyn-driven K+ selective channelrhodopsin for optogenetic inhibition of neurons. These AAV preparations are suitable purity for injection into animals.

Peter Hegemann, Johannes Vierock

Vierock et al Sci Adv. 2022 Nov 16:eadd7729.

July 30, 2025

Academic Institutions and Nonprofits only

#37825-AAV11.T

Ready-to-use AAV11 trial size particles produced from pAAV-CAG-GFP (#37825). In addition to the viral particles, you will also receive purified pAAV-CAG-GFP plasmid DNA. CAG-driven GFP expression. These AAV preparations are suitable purity for injection into animals.

Edward Boyden

July 16, 2025

Academic Institutions and Nonprofits only

#159605-AAV9

Ready-to-use AAV9 particles produced from pAAV-CAG-NIR-GECO2G (#159605). In addition to the viral particles, you will also receive purified pAAV-CAG-NIR-GECO2G plasmid DNA. CAG-driven expression of the near-infrared calcium indicator NIR-GECO2G. These AAV preparations are suitable purity for injection into animals.

Robert Campbell

Qian et al PLoS Biol. 2020 Nov 24;18(11):e3000965.

Dec. 18, 2024

Academic Institutions and Nonprofits only

#213915-PHPeB

Ready-to-use AAV PHP.eB particles produced from pAAV_BiLAMP5e3_ChR2_mCherry (#213915). In addition to the viral particles, you will also receive purified pAAV_BiLAMP5e3_ChR2_mCherry plasmid DNA. Expression of mCherry-tagged channelrhodopsin-2 under the control of the Lamp5 interneuron-targeting enhancer E3. These AAV were produced with the PHPeB serotype, which permits efficient transduction of the central nervous system. These AAV preparations are suitable purity for injection into animals.

Gordon Fishell

Furlanis et al Neuron. 2025 May 21;113(10):1525-1547.e1

Dec. 2, 2024

Academic Institutions and Nonprofits only

#218871-AAV1

Ready-to-use AAV1 particles produced from pGP-AAV-GFAP-iGABASnFR2-WPRE (#218871). In addition to the viral particles, you will also receive purified pGP-AAV-GFAP-iGABASnFR2-WPRE plasmid DNA. GFAP-driven expression of the improved GABA sensor iGABASnFR2 (positive change in fluorescence). These AAV preparations are suitable purity for injection into animals.

GENIE Project

Kolb et al eLife. 2026 Mar 18;14:RP108319. doi: 10.

Sept. 27, 2024

Academic Institutions and Nonprofits only

#218876-AAV1

Ready-to-use AAV1 particles produced from pGP-AAV-syn-iGABASnFR2(no bind)-WPRE (#218876). In addition to the viral particles, you will also receive purified pGP-AAV-syn-iGABASnFR2(no bind)-WPRE plasmid DNA. Syn-driven expression of the improved GABA sensor control iGABASnFR2(no bind) (no change in fluorescence). These AAV preparations are suitable purity for injection into animals.

GENIE Project

Kolb et al eLife. 2026 Mar 18;14:RP108319. doi: 10.

Sept. 27, 2024

Academic Institutions and Nonprofits only

#128486-AAV9

Ready-to-use AAV9 particles produced from pAAV-CAG-FLEx-iSeroSnFR (#128486). In addition to the viral particles, you will also receive purified pAAV-CAG-FLEx-iSeroSnFR plasmid DNA. CAG driven, Cre-dependent expression of iSeroSnFR. These AAV preparations are suitable purity for injection into animals.

Lin Tian

Unger et al Cell. 2020 Dec 12. pii: S0092-8674(20)31

Sept. 27, 2024

Academic Institutions and Nonprofits only

#191728-PHPeB

Ready-to-use AAV PHP.eB particles produced from AiP12408 - pAAV-AiE0600m-minBG-SYFP2-WPRE3-BGHpA (Alias: CN2408) (#191728). In addition to the viral particles, you will also receive purified AiP12408 - pAAV-AiE0600m-minBG-SYFP2-WPRE3-BGHpA (Alias: CN2408) plasmid DNA. SYFP2 expression in striatal and neocortical Sst-Chodl neurons. These AAV were produced with the PHPeB serotype, which permits efficient transduction of the central nervous system. These AAV preparations are suitable purity for injection into animals.

Allen Institute for Brain Science, Jonathan Ting

Hunker et al Neuron. 2025 May 21;113(10):1507-1524.e1

July 15, 2024

Academic Institutions and Nonprofits only